Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sickling Disorder Due to Hemoglobin S
Interventions
131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging
Drug · Radiation · Procedure
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Conditions
Renal Impairment
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Miami, Florida + 1 more
Conditions
Sickle Cell Disease
Interventions
Plerixafor, Busulfan, BIVV003
Biological · Drug · Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Oakland, California • Sacramento, California • Atlanta, Georgia + 2 more
Conditions
Sickle Cell Disease
Interventions
L-citrulline tablets, 1000 mg
Drug
Lead sponsor
Angiogenix
Industry
Eligibility
10 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Sickle Cell Disease
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Anemia, Sickle Cell
Interventions
SELFY (Self Management for Youth with SCD)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Sickle Cell Disease
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Louisville, Kentucky • Durham, North Carolina • Pittsburgh, Pennsylvania
Conditions
Anemia, Sickle Cell
Interventions
HBI-002
Drug
Lead sponsor
Hillhurst Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Conditions
Sickle Cell Anemia
Interventions
Measurement of carbon monoxide level in exhaled breath
Other
Lead sponsor
Ashutosh Lal
Other
Eligibility
5 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Oakland, California
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Healthy Volunteers, Anemia, Sickle Cell
Interventions
AG-946, AG-946 Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
Completed Phase 1Phase 2 Interventional Results available

Simvastatin (Zocor) Therapy in Sickle Cell Disease

NCT00508027
Conditions
Sickle Cell Disease
Interventions
Simvastatin
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
13 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Conditions
Sickle Cell Disease
Interventions
Pociredir
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Riverdale, Georgia + 3 more
Conditions
Sickle Cell Disease
Interventions
Femoral Nerve Block
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Anemia, Sickle Cell
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Sickle Cell Anemia, Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Kresge Eye Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Healthy, Sickle Cell Anemia
Interventions
Placebo, PF-07209326
Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
16
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
Conditions
Sickle Cell Disease
Interventions
Zileuton
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Conditions
Sickle Cell Disease
Interventions
AB1
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina
Conditions
Sickle Cell Disease
Interventions
ICL670
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Conditions
Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 4 more